Prelude Therapeutics Incorporated
PRLD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $70 | $187 | $208 | $430 |
| - Cash | $12 | $25 | $31 | $32 |
| + Debt | $18 | $17 | $2 | $2 |
| Enterprise Value | $75 | $179 | $179 | $400 |
| Revenue | $7 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $7 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| EBITDA | -$138 | -$131 | -$122 | -$113 |
| % Margin | -1,970.6% | – | – | – |
| Net Income | -$127 | -$122 | -$115 | -$112 |
| % Margin | -1,816.8% | – | – | – |
| EPS Diluted | -1.68 | -2.02 | -2.27 | -2.33 |
| % Growth | 16.8% | 11% | 2.6% | – |
| Operating Cash Flow | -$103 | -$107 | -$84 | -$84 |
| Capital Expenditures | -$1 | -$4 | -$3 | -$2 |
| Free Cash Flow | -$104 | -$111 | -$87 | -$86 |